The round was led by Laronde's founding company, Flagship Pioneering. Endless RNA is an "engineered form of RNA that can be programmed to express therapeutic proteins inside the body," according to the firm. Endless RNA is redosable, and it can be administered through simple delivery mechanisms, resulting in highly tunable protein levels. This allows for controlled expression of secreted peptides, proteins, antibodies, and vaccine constructs through an array of delivery options.

Additional investors include T. Rowe Price Associates, Invus, the Canada Pension Plan Investment Board, and Fidelity Management and Research, according to Laronde.

Flagship Pioneering unveils eRNA platform from Laronde
Flagship Pioneering unveiled its Laronde platform for the development of endless RNA (eRNA), a novel, engineered form of RNA that can be programmed to...